| Symbol | DNTH |
|---|---|
| Name | DIANTHUS THERAPEUTICS, INC. /DE/ |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 7 TIMES SQUARE, NEW YORK, NY 10036 |
| Telephone | 929-999-4055 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001690585 |
| Description | None |
(19% Negative) DIANTHUS THERAPEUTICS, INC. /DE/ (DNTH) Reports Q2 2026 Financial Results
Read moreDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Read moreDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form SCHEDULE 13G - Dianthus Therapeutics, Inc. /DE/ <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0002012383-26-001740 <b>Size:</b> 11 KB
Read moreSavitz Ryan 🟡 adjusted position in 8.2K shares (1 derivative) of Dianthus Therapeutics, Inc. /DE/ (DNTH) at $89.84 ($1.0M) Transaction Date: Apr 09, 2026 | Filing ID: 000006
Read more📋 RYAN SAVITZ (Officer) plans to sell 8K shares of DIANTHUS THERAPEUTICS INC (at $87.48 each, total $719K) Filed: Apr 09, 2026 | ID: 003357
Read moreNew Form ARS - Dianthus Therapeutics, Inc. /DE/ <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001690585-26-000014 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Dianthus Therapeutics, Inc. /DE/ <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001690585-26-000013 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Dianthus Therapeutics, Inc. /DE/ <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001690585-26-000012 <b>Size:</b> 6 MB
Read moreDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more